Iridian Asset Management’s Elicio Therapeutics ELTX Stock Holding History

Iridian Asset Management’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$321K	Buy	+30,051	New	+$290K	0.13%	40

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Iridian Asset Management's ELTX Position: Q1 2026 in Review

Iridian Asset Management opened a new position in Elicio Therapeutics (ELTX) in Q1 2026: 30,051 shares worth $321K. The stake represents 0.13% of the portfolio and ranks #40 among its holdings.

47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

Iridian Asset Management held 30,051 shares of Elicio Therapeutics worth $321K as of Q1 2026.
Elicio Therapeutics was a new Iridian Asset Management position in Q1 2026.
Elicio Therapeutics made up 0.13% of Iridian Asset Management's portfolio in Q1 2026, its #40 holding.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Iridian Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.